Invaio Sciences announces acquisition of Peptyde Bio

Peptyde Bio’s technology complements Invaio’s AI/ML-enabled discovery platform. (Image source: Invaio Sciences)

Bio platform company, Invaio Sciences has announced the acquisition of agtech startup, Peptyde Bio to bring an established platform and IP portfolio that enables Invaio to speed up the design and discovery of biologically active peptides capable of sustainably protecting crops from pests and disease

The acquisition brings together an established platform and IP portfolio, enabling Invaio to speed up the design and discovery of biologically active peptides that can protect crops from pests and disease in a more sustainable manner. Designed to produce nature-positive solutions for farmers, Invaio's pioneering innovation approach combines new environment friendly active ingredients possessing breakthrough solutions that protect and deliver these actives. 

This approach is driven by two critical research areas namely:

1.  A state-of-the-art artificial intelligence- and machine learning-enabled Discovery Engine that identifies and designs more targeted biological actives to control crop pests and diseases, addressing sustainability concerns around traditional crop protection treatments in vegetables, row crops and perennials.

2. Programming and deploying Biological Delivery Systems to improve the performance of actives and protect them by delivering exactly where they need to go and quickly biodegrading once their job is done. 

“This acquisition adds Peptyde Bio’s portfolio of confirmed peptide lead candidates for use in crop protection to our existing pipeline. When combined with our innovative biological delivery systems, we are uniquely positioned to offer growers more natural, efficient and effective solutions to protect their crops,” said Ignacio Martinez, founding CEO of Invaio. “It is a truly exciting time for Invaio and the industry as we accelerate the leap to more nature-positive solutions for farmers.”

Czymmek, PhD, CTO of Peptyde Bio stated that the company had created a large pipeline of peptides with novel modes of action. "We are looking forward to integrating our technology into the Invaio discovery engine and delivery platform."

For more information, visit: